EcoDrugPlus

Substance-P Receptor-Like

Ensembl ID : ENSSTUG00000049307
Gene Symbol: LOC115159784
3 Cross references
187 Possible Orthologues:

Substance-P Receptor-Like

Ensembl ID : ENSSTUG00000023545
Gene Symbol: LOC115203872
3 Cross references
188 Possible Orthologues:

Synaptic Vesicular Amine Transporter-Like

Ensembl ID : ENSSTUG00000002972
Gene Symbol: LOC115193833
3 Cross references
217 Possible Orthologues:

Synuclein Alpha

Ensembl ID : ENSSTUG00000013980
Gene Symbol: SNCA
1 Cross references
183 Possible Orthologues:

Synuclein Alpha

Ensembl ID : ENSSTUG00000003984
Gene Symbol: SNCA
1 Cross references
183 Possible Orthologues:

Tachykinin Receptor 1

Ensembl ID : ENSSTUG00000001614
Gene Symbol: TACR1
3 Cross references
190 Possible Orthologues:

Tachykinin Receptor 1

Ensembl ID : ENSSTUG00000020015
Gene Symbol: TACR1
3 Cross references
190 Possible Orthologues:

Tachykinin Receptor 3

Ensembl ID : ENSSTUG00000017330
Gene Symbol: TACR3
3 Cross references
242 Possible Orthologues:

Target Of Rapamycin Complex Subunit Lst8

Ensembl ID : ENSSTUG00000000921
Gene Symbol: LOC115201358
3 Cross references
151 Possible Orthologues:

Telomerase Reverse Transcriptase

Ensembl ID : ENSSTUG00000038585
Gene Symbol: TERT
3 Cross references
189 Possible Orthologues:

Thromboxane A2 Receptor-Like

Ensembl ID : ENSSTUG00000034158
Gene Symbol: LOC115151537
3 Cross references
186 Possible Orthologues:

Thromboxane A2 Receptor-Like

Ensembl ID : ENSSTUG00000002480
Gene Symbol: LOC115157972
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).